Skip to content
Homepage
Author:
Zepto Life Technology
Posted Date:
August 11, 2026
NIAID Awards Zepto Life Technology Contract Valued at Up to $8.9 Million to Advance the First Deployable Liquid Biopsy Platform for Infectious Disease
Zepto Life Technology
August 11, 2026
Zepto Life Technology Introduces FungiFlex® Pneumocystis jirovecii and FungiFlex® Mold Plus
Zepto Life Technology
July 15, 2026
Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections
Zepto Life Technology
June 3, 2026
